Curated CRC research, accessible, accurate, actionable

The CRC Digest

Wednesday, October 28, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  Blood-based Shield test detects 83% of colorectal cancers but only 13% of advanced precancerous lesions

  In the large-scale ECLIPSE study of average-risk individuals, the Shield cell-free DNA assay showed 83.1% sensitivity for colorectal cancer but only 13.2% sensitivity for advanced precancerous lesions, highlighting a key limitation of blood-based screening. (Diagnostics)

• ◇ RESEARCH

  Multiple intratumoral bacteria show stronger association with colorectal cancer than single species

  A Vietnamese cohort study found that co-detection of three bacterial species (F. nucleatum, A. muciniphila, and eae+ E. coli) was associated with a 21-fold increased odds of colorectal cancer compared to polyps, suggesting community-level bacterial interactions may drive tumor development. (Microorganisms)

• ▸ TREATMENT

  Inflammation-nutrition score predicts response to neoadjuvant therapy in rectal cancer

  In 312 patients with locally advanced rectal cancer, a low pretreatment inflammation-nutrition prognostic score (INPS) was independently associated with higher response rates (61% vs. 29%) and pathological complete response (39% vs. 12%), outperforming PD-L1 testing alone. (Front Genet)

• ♥ LIVING WITH CRC

  Elevated troponin before chemotherapy predicts cardiovascular events during treatment

  Among 180 colorectal cancer patients starting 5-fluorouracil-based chemotherapy, baseline high-sensitivity troponin T above 14 ng/L was independently associated with major cardiovascular events, with more than half occurring within the first two treatment cycles. (Front Cardiovasc Med)

Today's research spans blood-based screening performance, bacterial communities in tumors, predictive biomarkers for neoadjuvant therapy, and cardiovascular monitoring during chemotherapy.